Abivax (ABVX) said Monday it closed its previously announced public offering of 7.36 million American depositary shares, including the full exercise of the underwriters' option to purchase additional ADSs.
The offering generated aggregate gross proceeds of approximately $920 million, with estimated net proceeds of approximately $874.1 million, according to a statement.
Abivax said the net proceeds, together with its current cash and cash equivalents, will fund operations into Q4 of 2029.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments